L'Oréal is directing significant investment into longevity science, reflecting a broader industry trend where beauty and wellness sectors are merging. The company's strategy focuses on understanding the 'skin exposome' – all external and internal factors influencing skin health over time. This includes environmental aggressors like UV radiation and climate, alongside personal elements such as genetics, diet, sleep, and stress. By analysing these impacts, L'Oréal aims to address both visible signs of aging and underlying cellular changes.
Personalisation stands as a cornerstone of L'Oréal's approach, acknowledging that individuals age differently. Caroline Delaunay, global head of evaluation intelligence, indicated a future built on diagnostics and tailored beauty solutions, encompassing topicals, devices, and soon, supplements. The launch of Cell Bioprint in January 2025 marks a key step, offering a diagnostic tool to assess skin aging below the surface and identify optimal active ingredients for an individual's longevity path.
To manage this complexity, L'Oréal has developed an AI longevity cloud. This tool maps the nine hallmarks of aging and connects them to biological pathways affecting skin and scalp. By understanding these connections and biomarkers, the company plans to design coordinated interventions for specific needs. The ultimate goal is a highly personalised longevity journey for each consumer, based on their biological age rather than chronological age.
Key ingredients driving this initiative include L'Oréal's proprietary Mexoryl for deep cellular changes and PDRN for mitochondrial energy. Efforts are also underway to stabilise Vitamin C for its role in cellular interconnections. This move by a major beauty player signals a shift towards scientifically backed, personalised approaches to extending skin healthspan, moving beyond cosmetic fixes to deeper biological interventions.
